{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Vicencio JM"],"funding":["Cancer Research Institute/Wade FB Thompson CLIP Reference Number CRI3645","Cancer Research UK","AstraZeneca","EU IMI2 IMMUCAN"],"pagination":["274"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8960767"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["13(3)"],"pubmed_abstract":["Over the past decade, immunotherapy delivered novel treatments for many cancer types. However, lung cancer still leads cancer mortality, and non-small-cell lung carcinoma patients with mutant EGFR cannot benefit from checkpoint inhibitors due to toxicity, relying only on palliative chemotherapy and the third-generation tyrosine kinase inhibitor (TKI) osimertinib. This new drug extends lifespan by 9-months vs. second-generation TKIs, but unfortunately, cancers relapse due to resistance mechanisms and the lack of antitumor immune responses. Here we explored the combination of osimertinib with anti-HER3 monoclonal antibodies and observed that the immune system contributed to eliminate tumor cells in mice and co-culture experiments using bone marrow-derived macrophages and human PBMCs. Osimert"],"journal":["Cell death & disease"],"pubmed_title":["Osimertinib and anti-HER3 combination therapy engages immune dependent tumor toxicity via STING activation in trans."],"pmcid":["PMC8960767"],"funding_grant_id":["C604/A27442","C1519/A27375","C604/A25135","C1519/A28682","C7675/A29313","176885","10029191","C1519/A16463","DCRPGF\\100009","C7893/A26233"],"pubmed_authors":["Capone E","Hochhauser D","Yarden Y","Clancy J","Lawler K","Gomes C","Parsons M","Arnold JN","Deng J","Alfano G","Chan JNE","Weitsman G","Vicencio JM","Coban O","Gordon P","Quezada SA","De-Souza K","Iacobelli S","Wong F","Hartley JA","Evans R","An Z","Dolcetti L","Treacy C","Barber PR","Chalk A","Ameer-Beg S","Ng K","Sala G","Gomez V","Pan T","Sosnowska D","Ng T","Monypenny J","Costoya C","Green R","Mustapha R","Savage C","Chen SH","Flores-Borja F"],"additional_accession":[]},"is_claimable":false,"name":"Osimertinib and anti-HER3 combination therapy engages immune dependent tumor toxicity via STING activation in trans.","description":"Over the past decade, immunotherapy delivered novel treatments for many cancer types. However, lung cancer still leads cancer mortality, and non-small-cell lung carcinoma patients with mutant EGFR cannot benefit from checkpoint inhibitors due to toxicity, relying only on palliative chemotherapy and the third-generation tyrosine kinase inhibitor (TKI) osimertinib. This new drug extends lifespan by 9-months vs. second-generation TKIs, but unfortunately, cancers relapse due to resistance mechanisms and the lack of antitumor immune responses. Here we explored the combination of osimertinib with anti-HER3 monoclonal antibodies and observed that the immune system contributed to eliminate tumor cells in mice and co-culture experiments using bone marrow-derived macrophages and human PBMCs. Osimert","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Mar","modification":"2025-04-21T17:31:40.238Z","creation":"2025-04-05T16:40:39.888Z"},"accession":"S-EPMC8960767","cross_references":{"pubmed":["35347108"],"doi":["10.1038/s41419-022-04701-3"]}}